Retrospective Evaluation of the Analgesic Effects of Molecular Target Agents Against Cancer Pain and Oxaliplatin-Induced Chronic Peripheral Neuropathy
Journal of Analytical Oncology(2022)
摘要
Epidermal growth factor receptor (EGFR) has received significant attention for its therapeutic potential for pain relief. The relief of neuropathic pain after treatment with anti-EGFR antibodies or tyrosine kinase inhibitors has been previously described. However, few reports have investigated the association of cancer-related nociceptive pain or chronic chemical induced peripheral neuropathy with the analgesic effects of EGFR inhibition. Therefore, we conducted a retrospective survey of 191 patients with colorectal cancer receiving chemotherapy plus molecular targeting drugs to examine the analgesic effects of anti-EGFR antibodies against either cancer pain or oxaliplatin-induced peripheral neuropathy. We identified a significant difference in the improvement rates of nociceptive pain between panitumumab- and bevacizumab-treated patients (100% vs. 9.1%; p < 0.01), but not oxaliplatin-induced peripheral neuropathy. In conclusion, panitumumab may be effective at reducing cancer-related nociceptive pain.
更多查看译文
关键词
cancer pain,analgesic effects,molecular target agents,oxaliplatin-induced
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要